Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 914-129-3 | CAS number: 12336-95-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
oral, rat, comparable to OECD 401, LD50 = 3530 mg/kg bw/d
inhalation, rat, acc to OECD 403, GLP, LC50 < 4.58 mg/L
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Proprietary study, reported in summary form only but in sufficent detail to allow reliable interpretation of the adequacy of the method and results
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- The study is not reported in great detail but appears to be broadly comparable to OECD 401; bodyweights were not measured and gross necropsy not performed.
- GLP compliance:
- no
- Remarks:
- study pre-dates GLP
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- Male Wistar rats (160-180 g) were obtained from Winkelmann (Germany) and were group housed (5 animals/cage)
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- No further details
- Doses:
- 1000, 3100, 3500, 4000, 4500 and 5000 mg/kg bw
- No. of animals per sex per dose:
- 10 males
- Control animals:
- no
- Details on study design:
- No further details
- Statistics:
- LD50 calculation according to the method of Fink & Hund (Arzneimittel-Forschung 15, 624; 1965)
- Preliminary study:
- Not reported
- Sex:
- male
- Dose descriptor:
- LDLo
- Effect level:
- 3 100 mg/kg bw
- Remarks on result:
- other: 1/10 rats
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 3 530 mg/kg bw
- 95% CL:
- 3 190 - 3 790
- Sex:
- male
- Dose descriptor:
- LD100
- Effect level:
- 5 000 mg/kg bw
- Mortality:
- Deaths occured at 3100 mg/kg bw (1), 3500 mg/kg bw (7), 4000 mg/kg bw (7), 4500 mg/kg bw (9) and 5000 mg/kg bw (10).
- Clinical signs:
- other: Signs of toxicity (emaciation, red staining of the eyes and nose, reduction in common parameters) were seen in all animals at dose levels of 3100 mg/kg bw and greater
- Gross pathology:
- Not reported
- Other findings:
- No other findings are detailed
- Interpretation of results:
- GHS criteria not met
- Remarks:
- Criteria used for interpretation of results: EU
- Conclusions:
- The LD50 of the test material was calculated to be 3530 mg/kg bw. Classification for acute oral toxicity according to current EU criteria is not required.
- Executive summary:
In a study comparable to OECD Test Guideline 401 Wistar rats (10 males/group) were gavaged with a single dose of the test material (in water) at dose levels of 1000, 3100, 3500, 4000, 4500 or 5000 mg/kg bw and observed for 14 days. Deaths occurred at 3100 mg/kg bw (1), 3500 mg/kg bw (7), 4000 mg/kg bw (7), 4500 mg/kg bw (9) and 5000 mg/kg bw (10) within 9 days of exposure. Signs of toxicity (emaciation, red staining of the eyes and nose, reduction in common parameters) were observed at dose levels of 3100 mg/kg bw and above. The LD50 was calculated to be 3530 (3190 -3790) mg/kg bw.
Reference
The results of the study are tabulated below. The LD50 in male rats was found to be >3100 mg/kg bw and was calculated to be 3530 (3190 -3790) mg/kg bw.
Dose level (mg/kg bw) |
No. animals |
Signs of toxicity |
Deaths |
Time of death |
1000 |
10 |
- |
- |
- |
3100 |
10 |
10 |
1 |
3h |
3500 |
10 |
10 |
7 |
2-9d |
4000 |
10 |
10 |
7 |
2-5d |
4500 |
10 |
10 |
9 |
2-7d |
5000 |
10 |
10 |
10 |
2-4d |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 3 530 mg/kg bw
- Quality of whole database:
- sufficient quality of the database
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 19 May to 18 September 2009
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Version / remarks:
- adopted 12 May 1981
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1300 (Acute inhalation toxicity)
- Version / remarks:
- 1998
- Qualifier:
- according to guideline
- Guideline:
- other: JMAFF Japanese MAFF Agrochemical Test Guidelines 12 Nohsan 8147
- Version / remarks:
- 2-1-12, 24 November 2000 and revision of 24 June 2001
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Rationale for alternative/additional species to rat (if applicable) : Han Wistar rats
- Source: Harlan UK Ltd
- Age at study initiation: less than 12 weeks
- Weight at study initiation: 200 g ± 15%
- Housing: in groups of five
- Diet (e.g. ad libitum): SQC Rat and Mouse Maintenance Diet No.1, Expanded (SDS Ltd., UK) ad libitum.
- Water (e.g. ad libitum): ad libitum.
- Acclimation period: 9 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 - 25
- Humidity (%): 40 to 70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12hrs/12hrs
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose only
- Vehicle:
- other: unchanged (no vehicle)
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure chamber volume: approximately 40 L
- Source and rate of air (airflow): 14 L/min
- System of generating particulates/aerosols: Rotating Brush Generator into a flow-through
- Method of particle size determination: gravimetrically using a Marple 298 Cascade impactor
- Temperature and humidity in air chamber: 20.8 °C, 21.1 %
TEST ATMOSPHERE
- Brief description of analytical method and equipment used: The test aerosol was generated from the test article, chromium hydroxide sulphate, using a Rotating Brush Generator into a flow-through (nose only) exposure chamber of approximately 40 L volume. The air flow was 14 L/min and provided 12 air changes per hour.
TEST ATMOSPHERE (if not tabulated)
- Particle size distribution: The mean particle size distribution (MMAD ± GSD) was 3.12 µm ± 1.79. 42.9-63.1% of the particles were below 3.5 µm in diameter.
- MMAD (Mass median aerodynamic diameter) / GSD (Geometric st. dev.): The protocol range for the particle size distribution is 1 – 4μm MMAD and 1 – 3 GSD - Analytical verification of test atmosphere concentrations:
- yes
- Remarks:
- The achieved aerosol concentration was measured gravimetrically prior to and at approximately half-hourly intervals throughout the exposure.
- Duration of exposure:
- 4 h
- Concentrations:
- Nominal concentration = 43.3 mg/L. The mean achieved aerosol concentration = 4.58 mg/L, with a range of 3.45 to 5.98 mg/L.
- No. of animals per sex per dose:
- Five
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observed daily for signs of ill health or overt toxicity. Weighing Day1, 2, 3, 7, 8, 9 and 14
- Necropsy of survivors performed: Yes, all animals were subject to a gross necropsy.
- Clinical signs including body weight: Huntched posture, unkempt, rales and piloerection were observed from most of the test group
- Other examinations performed: organ weights, histopathology - Statistics:
- Not performed.
- Preliminary study:
- Not applicable.
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- < 4.58 mg/L air (analytical)
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Mortality:
- 6/10 animals were terminated prematurely due to the severity of the clinical signs observed: 1 male and 1 female were terminated on Day 1; 1 female was terminated on Day 3, a second on Day 7 and a third on Day 8; 1 male was terminated on Day 11. One male was found dead on Day 10.
- Clinical signs:
- other: gasping, rales, vocalisation, dyspnoea, hunched posture, unkempt coat, piloerection, hypothermia, semi-closed eyes, and distended abdomen
- Remarks:
- for detailed information please refer to field 'Any other information'
- Body weight:
- - greater than 10% body weight loss
: Most decedent animals steadily lost weight until their day of death, with some losing 31-34% of the pre-exposure body weight.
All animals lost body weight following exposure to the test article. Surviving animals started to gain weight from Day 5, although none reached their pre-exposure weight by the end of the observation period. - Gross pathology:
- Macroscopic findings were generally unremarkable, except dark lungs were noted in one male and three female decedents.
- Conclusions:
- The LC50 is considered to be below 4.58 mg/L.
- Executive summary:
An acute inhalation toxicity study according to OECD Test Guideline 403 under GLP was performed in rats. Five male and five female Han Wistar rats underwent a single 4 -hour nose only inhalation exposure to chromium hydroxide sulphate at a mean atmospheric exposure level of 4.58 mg/L. The test compound was poorly tolerated, causing persistant clinical signs. Seven out of ten animals died during the course of the study. The LC50 is therefore considered to be below 4.58 mg/L.
Reference
The LC50 is considered to be below 4.58 mg/L.
Clinical signs
Severe clinical signs were observed in the majority of the animals, and persisted throughout the observation period. Signs included: gasping, rales, vocalisation, dyspnoea, hunched posture, unkempt coat, piloerection, hypothermia, semi-closed eyes, and distended abdomen
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 4 580 mg/m³ air
- Physical form:
- inhalation: dust / mist
- Quality of whole database:
- sufficient quality of the database
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
An acute oral toxicity study is available for the material 'Chromsal B' (chromium hydroxide sulphate / sodium sulphate), which shows low toxicity. This study was reported briefly, but in sufficient detail to enable confident evaluation of the method and the reliability of the results. The calculated LD50 from this study of 3530 mg/kg bw shows that the substance is of low toxicity by this route.
An acute inhalation study was performed according to OECD Test Guideline 403 and GLP. Male and female Han Wistar rats underwent a single 4 -hour nose only inhalation exposure to chromium hydroxide sulphate at a mean atmospheric exposure level of 4.58 mg/L. The test compound was poorly tolerated, causing persistent clinical signs. Seven out of ten animals died during the course of the study. The LC50 is therefore considered to be below 4.58 mg/L.
Justification for classification or non-classification
Based on the available results the registered substance is classified as Acute tox 4 (H332: Harmful if inhaled) according to Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.